Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells consist of a defined proportion of CD4 and CD8 positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domain and a truncated human epidermal growth factor receptor (EGFRt), which has potential cytotoxic activity against CD19-expressing tumor cells (NCI Thesaurus). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C137866 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells | Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells | 0 | 2 |
Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B | Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells Iomab-B | 0 | 1 |